Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Follow us on Google+Follow us on TwitterFind us on LinkedInFind Us on FacebookSubscribe to our RSS FeedsSubscribe to our YouTube ChannelFind us on RebelMouse

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for May 10, 2013 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version   



Dr. Richard Gordon, Ramapo Ophthalmology, AnnouncesParticipation in National Clinical Research Trial For Treatment of Keratoconus and Corneal Ectasia

Dr. Richard Gordon of Ramapo Ophthalmology provides AVEDRO, a Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of the KXL System with VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes
 
x-small text small text medium text large text

    POMONA, NY, May 10, 2013 /24-7PressRelease/ -- Ramapo Ophthalmology Associates is pleased to announce their participation in a national clinical research trial to examine an investigational treatment to stop or slow the progression of Keratoconus and Corneal Ectasia. The study, to be conducted by prominent Ophthalmologist Dr. Richard Gordon is open to participants who are 18 years of age or older who were diagnosed with Keratoconus or were diagnosed with Corneal Ectasia after they received refractive surgery (e.g. LASIK, PRK). Participants are required to make at least eight office visits over a 12- month period.

The FDA approved cornea treatment study, which is sponsored by The American-European Congress of Ophthalmic Surgery (ACO) and Avedro Inc., is being conducted in 100 clinics in the U.S. The purpose is to study if this one-time treatment will strengthen the cornea so that the progress of Keratoconus and Corenal Ectasia is slowed or stopped. The treatment has been performed on thousands of patients in Japan and Europe.

Dr. Gordon, a Keratoconus specialist, will use an ultraviolet-A illumination device (UVA light treatment), commonly known as KXL System, in combination with VibeXeye drops to treat the cornea.

For more information about the cornea study and to schedule an appointment, please call Evelyn Bay at Ramapo Ophthalmology Associates at 845-362-1450 or email her at ebay@ramapoeyecare.com.

Waiting Room Solutions is a leading web-based provider of fully integrated EHR and Practice Management software solutions for the Urgent Care Specialty. WRS seamlessly integrates all of the clinical and business functions required for healthcare providers, including: Electronic Health Records, Revenue Cycle Management, Personal Health Records, electronic prescribing (ERx), scheduling, website creation and content management, , messaging, fax, order tracking, and billing -- all at an affordable price. Waiting Room SolutionsPractice Management System, Version 3, is a CCHIT Certified 2006 Ambulatory EHR. It has been designed and built by successful medical professionals, who leveraged their expertise to help other healthcare providers with similar issues. Waiting Room Solutions continues to be recognized for its cutting edge technology.

More information on Waiting Room Solutions can be found at http://www.WaitingRoomSolutions.com or by calling 1-866-WRS-4EMR.

Inquiries can be sent to:
sales@waitingroomsolutions.com
Waiting Room Solutions
866-977-4367



---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #

Read more Press Releases from Waiting Room Solutions:

Contact Information:
Waiting Room Solutions
Waiting Room Solutions

Goshen, NY 10924
United States
Voice: (866)977-4367
E-Mail: Email us Here
Website: Visit Our Website
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7PressRelease. We are unable to assist you with any information regarding this release. 24-7PressRelease disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.